Each of these antibodies targets an IgV-domain containing immune receptor expressed by activated T cells (PD-1 and CTLA-4), or tumor or tumor-associated myeloid cells (PD-L1), that functions to inhibit antigen-dependent T cell responses. Here, CTLA4 is linked to neoplasm.